

DAFTAR PUSTAKA

1. Argirion I, Zarins KR, Defever K, Suwanrungruang K, Chang JT, Pongnikorn D, et al. Temporal Changes in Head and Neck Cancer Incidence in Thailand Suggest Changing Oropharyngeal Epidemiology in the Region. Am Soc Clin Oncol. 2019;1–11.
2. Saleh K, Eid R, Haddad FGH, Khalife-Saleh N, Kourie HR. New developments in the management of head and neck cancer – Impact of pembrolizumab. Ther Clin Risk Manag. 2018;14:295–303.
3. Koyfman SA, Ismaila N, Crook D, D'Cruz A, Rodriguez CP, Sher DJ, et al. Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx : ASCO Clinical Practice Guideline. Am Soc Clin Oncol. 2019;37:1–22.
4. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr [Internet]. 2017;1–25. Available from: <http://dx.doi.org/10.1016/j.clnu.2017.06.017>
5. Ling HH, Yeh KY, Ng SH, Wang CH, Lai CH, Wu TH, et al. Determining malnutrition assessment criteria to predict one-year mortality for locally advanced head and neck cancer patients undergoing concurrent chemoradiotherapy. Nutrients. 2020;12(3):1–13.
6. Mascarella MA, Mannard E, Daniela S, Wurzba S, Zeitouni A. Neutrophil-

- to-lymphocyte ratio in head and neck cancer prognosis : A systematic review and meta-analysis. Head Neck. 2018;00:1–10.
7. Jian-hui C, Iskandar EA, Cai S, Chen C, Wu H, Xu J, et al. Significance of Onodera's prognostic nutritional index in patients with colorectal cancer : a large cohort study in a single Chinese institution. Tumor Biol. 2016;37:3277–83.
 8. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;(January):1–8.
 9. Pastore CA, Orlatidi SP, González MC. Association between an inflammatory-nutritional index and nutritional status in cancer patients. Nutr Hosp. 2013;28(1):188–94.
 10. Argiris A, Karamouzis M V, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695–709.
 11. Polverini PJ, Lingen MW. A History of Innovations in the Diagnosis and Treatment of Oral and Head and Neck Cancer. J Dent Res. 2019;98(5):489–97.
 12. Langius J. More than 10% weight loss in head and neck cancer patients during radiotherapy is independently associated with deterioration in quality of life. In: Langius J, editor. Malnutrition in patients with head and neck cancer during treatment : concepts and clinical implications. Amsterdam: GVO drukkers & vormgevers B.V.; 2015. p. 21–36.

13. Cohen N, Fedewa S, Chen AY. Epidemiology and Demographics of the Head and Neck Cancer Population. *Oral Maxillofac Surg Clin N Am* [Internet]. 2018;30(4):381–95. Available from: <https://doi.org/10.1016/j.coms.2018.06.001>
14. Marur S, Forastiere AA. Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment. *Mayo Found Med Educ Res*. 2008;83(4):489–501.
15. Chow LQM. Head and Neck Cancer. *N Engl J Med*. 2020;382:60–72.
16. Bungan NTO, Liyah SHA, Wijayanti N, Fachiroh J. Epidemiologi, Stadium, dan Derajat Diferensiasi Kanker Kepala dan Leher. Biogenesis. 2015;3(1):47–52.
17. Jou A, Hess J. Epidemiology and Molecular Biology of Head and Neck Cancer. *Oncol Res Treat*. 2017;40:328–32.
18. Lester S, Yang W-Y. Principles and management of head and neck cancer. *Surgery* [Internet]. 2012;30(11):617–23. Available from: <http://dx.doi.org/10.1016/j.mpsur.2012.09.002>
19. Brockstein B, Masters G. Head and Neck Cancer. Rosen ST, editor. New York: Kluwer Academic; 2004. 1–370 p.
20. Diagnosis and management of head and neck cancer. Scotland: Scottish Intercollegiate Guidelines Network; 2006. 1–96 p.
21. Shaw R, Beasley N. Aetiology and risk factors for head and neck cancer :

United Kingdom National Multidisciplinary Guidelines. J ofLaryngology Otol. 2016;130:9–12.

22. Gregoire V, Levebvre J-L, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Supplement 5):184–6.
23. Hadi S, Kurniawan C, Budiono J. Review Eicosapentaenoic Acid as Adjuvant for Cachexia in Cancer ’ s Patients. Int J Integr Heal Sci. 2015;3(1):1–6.
24. Castillo-martínez L, Castro-eguiluz D, Copca-mendoza ET, Pérez-camargo DA, Reyes-torres CA, Ávila EA, et al. Nutritional Assessment Tools for the Identification of Malnutrition and Nutritional Risk Associated with Cancer Treatment. Rev Investig Clin. 2018;70:121–5.
25. Makhija S, Baker J. The Subjective Global Assessment : A Review of Its Use in Clinical Practice. Nutr Clin Pract. 2008;23(4):405–9.
26. de las Peñas R, Majem M, Perez-Altozano J, Virizuela JA, Cancer E, Diz P, et al. SEOM clinical guidelines on nutrition in cancer patients (2018). Clin Transl Oncol [Internet]. 2019;21(1):87–93. Available from: <https://doi.org/10.1007/s12094-018-02009-3>
27. Fruchtenicht AVG, Poziomyck AK, Reis AM Dos, Galia CR, Kabke GB, Moreira LF. Inflammatory and nutritional statuses of patients submitted to resection of gastrointestinal tumors. Rev Col Bras Cir. 2018;45(2):1–11.

28. Faria SS, Fernandes Jr CP, Silva MJB, Lima VC, Fontes W, Freitas-junior R, et al. The neutrophil-to-lymphocyte ratio : a narrative review. *ecancer Med Sci.* 2016;10(702):1–12.
29. Silva TH, Schilithz AOC, Peres WAF, Murad LB. Neutrophil-lymphocyte ratio and nutritional status are clinically useful in predicting prognosis in colorectal cancer patients. *Nutr Cancer* [Internet]. 2019;1–11. Available from: <https://doi.org/10.1080/01635581.2019.1679198>
30. Tan YG, Sia J, Huang HH, Lau WKO. Neutrophil-to-lymphocyte ratio independently predicts advanced pathological staging and poorer survival outcomes in testicular cancer. *Investig Clin Urol.* 2019;60(3):176–83.
31. Pessanha L L, Schmidt Mo M, Ribeiro Ca L, Depolo Ech Á, Fraga Silv NM, Blaser Pet G, et al. Neutrophil-to-lymphocyte Ratio and Nutritional Status in Patients with Cancer in Hospital Admission. *Int J Cancer Res.* 2019;15(1):9–16.
32. Anissa L, Wulandari Y, Nurwidya F. Association Between Nutritional Status and Neutrophil Lymphocyte Ratio in Patients with Lung Cancer at Persahabatan Hospital, Indonesia Lidya. *Int J Nutr Pharmacol Neurol Dis* |. 2021;11:119–205.
33. Bojaxhiu B, Templeton AJ, Elicin O, Shelan M, Zaugg K, Walser M, et al. Relation of baseline neutrophil-to- lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. *Radiat Oncol.* 2018;13(216):1–9.

34. Forget P, Khalifa C, Defour JP, Latinne D, Pel MC Van, Kock M De. What is the normal value of the neutrophil-to-lymphocyte ratio ? BMC Res Notes. 2017;10(12):1–4.
35. Sato YU, Gonda K, Harada M, Tanisaka Y, Arai S, Mashimo Y, et al. Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition , inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma. Biomed Reports. 2017;7:79–84.
36. Borges TC, Gomes TL, Pichard C, Laviano A, Pimentel GD. High neutrophil to lymphocytes ratio is associated with sarcopenia risk in hospitalized cancer patients. Clin Nutr [Internet]. 2020;1–5. Available from: <https://doi.org/10.1016/j.clnu.2020.05.005>
37. Yang L, Xia L, Wang Y, Hong S, Chen H, Liang S, et al. Low Prognostic Nutritional Index (PNI) predicts unfavorable distant metastasis-free survival in nasopharyngeal carcinoma: A propensity score-matched analysis. PLoS One. 2016;11(7):1–18.
38. Diaz C, Calderillo-Ruiz G, Ramos-Ramirez M, Herrera M, Manuel F, Horacio L, et al. Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population. Ann Oncol [Internet]. 2019;30(July):iv95. Available from: <https://doi.org/10.1093/annonc/mdz155.342>
39. Abe A, Hayashi H, Ishihama T, Furuta H. Prognostic impact of the

- prognostic nutritional index in cases of resected oral squamous cell carcinoma: a retrospective study. BMC Oral Health [Internet]. 2021;21(1):1–11. Available from: <https://doi.org/10.1186/s12903-021-01394-6>
40. Hsieh MC, Rau KM, Chiang PH, Sung MT, Lan J, Luo HL, et al. Impact of prognostic nutritional index on overall survival for patients with metastatic urothelial carcinoma. *J Cancer*. 2018;9(14):2466–71.
41. Nathania N, Dewi YA, Permana AD. Profile of head neck cancer patients from 2013-2018 at Dr . Hasan Sadikin General Hospital Bandung. *Orli*. 2020;51(2):141–5.
42. Sabatini ME, Chiocca S. Human papillomavirus as a driver of head and neck cancers. *Br J Cancer* [Internet]. 2020;122(3):306–14. Available from: <http://dx.doi.org/10.1038/s41416-019-0602-7>
43. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. *Nat Rev Dis Prim*. 2020;6(1):1–22.
44. da Silva Fink J, Daniel de Mello P, Daniel de Mello E. Subjective global assessment of nutritional status - A systematic review of the literature. *Clin Nutr* [Internet]. 2015;34(5):1–32. Available from: <http://dx.doi.org/10.1016/j.clnu.2014.12.014>
45. Darmojo RT. Aplikasi Screening Gizi Menggunakan Metode Subjective Global Assessment. Univ Muhammadiyah Surakarta. 2018;1–19.

46. Takenaka Y, Oya R, Kitamiura T, Ashida N, Shimizu K, Takemura K, et al. Prognostic role of neutrophil-to-lymphocyte ratio in head and neck cancer: A meta-analysis. *Head Neck.* 2017;1–9.
47. Fanetti G, Polesel J, Fratta E, Muraro E, Lupato V, Alfieri S, et al. Prognostic nutritional index predicts toxicity in head and neck cancer patients treated with definitive radiotherapy in association with chemotherapy. *Nutrients.* 2021;13(4):1–12.
48. Bossi P. Prognostic Nutritional Index: An easy nutritional screening for patients with head and neck cancer? *ESMO Open.* 2018;3(6):1–2.
49. Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, et al. Pathogenesis and treatment options of cancer related anemia: Perspective for a targeted mechanism-based approach. *Front Physiol.* 2018;9(SEP):1–20.
50. Xishan Z, Ye Z, Feiyan M, Liang X, Shikai W. The role of prognostic nutritional index for clinical outcomes of gastric cancer after total gastrectomy. *Sci Rep [Internet].* 2020;10(1):1–10. Available from: <https://doi.org/10.1038/s41598-020-74525-8>
51. Jeyakumar A, Brickman TM, Jeyakumar A, Doerr T. Review of nasopharyngeal carcinoma. *Ear, Nose Throat J.* 2006;85(3).

Lampiran 1

KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN

KOMITE ETIK PENELITIAN KESEHATAN

RSPDN UNIVERSITAS HASANUDDIN

RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR.

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.30 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari, MMed, PhD, Sp.GK Telp. 081241850858. 0411 5780103. Fax: 0411 581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 196/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 26 Maret 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21030145	No Sponsor Protokol	
Peneliti Utama	dr. Silvia	Sponsor	
Judul Peneliti	Analisis Marker Inflamasi Terhadap Status Nutrisi Pada Pasien Kanker Kepala dan Leher di RSUP Dr Wahidin Sudirohusodo Periode 2018-2020(Kajian terhadap Ratio Netrofil/Limfosit (NLR) dan Onodera Prognostic Nutrition Index(mPNI))		
No Versi Protokol	1	Tanggal Versi	8 Maret 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 26 Maret 2021 sampai 26 Maret 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mempatuhi semua peraturan yang ditentukan